Why is the new 'Female Viagra' so controversial?

시알리스, a substance intended for pre-menopausal women with low sexual desire, has been approved by the main public health body in the United States.

But does it really work? And what are the health concerns associated with it?

Women in the United States now have access to a new libido-enhancing drug that has been hailed as the new "female 시알리스".

The Food and Drug Administration (FDA), the US government agency that ensures drugs are safe for consumers, approved Vyleesi.

But in the weeks that followed, he also reignited the debate about the role of drugs in such complex issues as sexual desire and libido.

The drug is called bremelanotide - Vyleesi is its brand name.

It is designed for young and old women - without symptoms of peri-menopause or menopause - but who suffer from Hypoactive Sexual Desire Disorder (TBDS).

Clinicians describe it as a regular and persistent lack of interest in sexual activity, and it is estimated to affect between 6% and 10% of women of childbearing age in the United States.

It's the second time the pharmaceutical industry has tried to find a "female 시알리스," and FDA approval has sparked controversy after doctors expressed doubts about the drug's effectiveness and said women were in danger by consuming these drugs.

So, does bremelanotide really work? And what are the health concerns associated with it?